Financial and Competing Interest Disclosure: SAW is the Chair (uncompensated) of the Scientific Advisory Board of Targeted Diagnostics and Therapeutics, Inc., which provided research funding that, in part, supported this study and which has a license to commercialize inventions related to this work. DSW is a shareholder in Targeted Diagnostics and Therapeutics, Inc.
Molecular staging individualizing cancer management†
Article first published online: 22 MAR 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Special Issue: Seminars in Surgical Oncology: Translational Work
Volume 105, Issue 5, pages 468–474, 1 April 2012
How to Cite
Mejia, A., Schulz, S., Hyslop, T., Weinberg, D. S. and Waldman, S. A. (2012), Molecular staging individualizing cancer management. J. Surg. Oncol., 105: 468–474. doi: 10.1002/jso.21858
- Issue published online: 22 MAR 2012
- Article first published online: 22 MAR 2012
- Manuscript Accepted: 7 DEC 2010
- Manuscript Received: 5 MAY 2010
- National Institutes of Health. Grant Numbers: CA75123, CA95026, CA112147
- Targeted Diagnostic & Therapeutics, Inc
- colorectal cancer;
- guanylyl cyclase C;
- quantitative reverse transcriptase-polymerase chain reaction;
- lymph nodes;
- metastatic disease;
- prognostic markers;
- predictive markers
Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468–474. © 2012 Wiley Periodicals, Inc.